SAN DIEGO, March 5, 2020 /PRNewswire/ -- Trovagene,
Inc. (Nasdaq: TROV), a clinical-stage,
Precision Cancer Medicine™ oncology therapeutics company
developing drugs that target cell division (mitosis) for the
treatment of various cancers including colorectal, prostate and
leukemia, today announced the nomination of three new board
members, James Armitage, MD,
Lâle White and Gary Pace, PhD,
proposed for election at the Company's annual meeting of
shareholders, scheduled for April 16,
2020.
Dr. Armitage is professor of internal medicine in the division
of hematology and oncology at the University
of Nebraska Medical Center, and formerly served as President
of the American Society of Clinical Oncology (ASCO), and as a
member of the ASCO Board of Directors. Lâle White is the Chief
Executive Officer of XIFIN, a financial cloud computing company,
and formerly Vice President of Finance for Laboratory Corporation
of America, one of the largest clinical reference laboratories in
the U.S. Dr. Pace is a director of Pacira Biosciences, Inc.,
Simavita Ltd and Antisense Therapeutics, and a seasoned
biopharmaceutical executive who co-founded several early-stage life
science companies.
"I am extremely pleased with the nominees proposed for election
to the board of directors," said Dr. Thomas
Adams, Chief Executive Officer and Chairman of Trovagene.
"Jim, Lâle and Gary bring expertise that is essential as we
continue to advance our onvansertib clinical development programs,
establish strategic partnerships with pharma/biotech companies and
optimize allocation of capital. We are confident that each nominee
will provide valuable insights and fresh perspectives while, at the
same time, working with us to maximize shareholder value."
"The board's new nominees are veteran biotech executives and
experts in their respective fields, each of which aligns with the
current and future growth strategy for Trovagene and compliments
the other board members' backgrounds and expertise," said Dr.
Rodney Markin, Chair of the
Corporate Governance and Nominating Committee.
About James D.
Armitage
James O. Armitage, M.D., has been
a Professor of Internal Medicine in the Division of Hematology and
Oncology at the University of Nebraska Medical
Center since 2003, after having served as chairman of the
department of internal medicine, dean of the college of medicine,
and in various other capacities since joining the Center in 1982.
He also holds a hospital appointment at Nebraska Medicine. Dr.
Armitage has authored or co-authored more than 600 articles, 108
book chapters and edited or co-edited 27 textbooks. He has
previously served as president of the American Society of Clinical
Oncology ("ASCO"), and as a member of the ASCO Board of Directors.
Dr. Armitage received a bachelor of science degree from the
University of Nebraska and a medical
degree from the University of Nebraska Medical
Center and completed his post-graduate training at the
University of Nebraska Medical Center
and the University of Iowa Hospitals
and Clinics.
About Lâle White
Lâle White is the Chief Executive Officer of XIFIN, Inc.
("XIFIN"), a financial cloud computing company, with over 25 years
of experience in information systems development and medical
billing. She lectures extensively on these topics and has consulted
for major laboratories and laboratory associations throughout the
U.S. Ms. White worked with HCFA and the U.S. Office of the
Inspector General to develop the first OIG Model Compliance
Program. She is a longstanding member of the California Clinical
Lab Association, where for the last eight years she has chaired the
state and federal contractor committees that work with the Medicare
Administrative Contractors and the Department of Health and Human
Services. Ms. White was previously Vice President of Finance for
Laboratory Corporation of America, one of the largest clinical
reference laboratories in the U.S., and its predecessor National
Health Laboratories, where she led the software development of
several accounts receivable, inventory, cost accounting and
financial management systems for the laboratory industry. Ms. White
previously was on the Board of bioTheranostics while it was a
BioMerieux subsidiary and CombiMatrix Corporation, until its
acquisition by Invitae Corporation in 2017. Ms. White has a
BA in finance and MBA from Florida
International University.
About Gary W. Pace
Gary W. Pace, Ph.D. has been a
director of Pacira Biosciences, Inc. since 2008, Antisense
Therapeutics since 2015, and Simavita Ltd. since 2016, as well as a
director of several private companies. He previously served
on the board of ResMed Inc. from 1994 to 2018, Transition
Therapeutics Inc. from 2002 to 2016 and ORxPharma Ltd. from 2001 to
2013. Dr. Pace is a seasoned biopharmaceutical executive with
over 40 years of experience in the industry. He has
co-founded several early stage life science companies, where he
brought products from the laboratory to commercialization.
Dr. Pace has contributed to the development of the biotechnology
industry through honorary university appointments and industry and
government committees. In 2003, he was awarded a Centenary
Medal by the Australian Government "for service to Australian
society in research and development" and was recognized as the 2011
Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace
holds a B.Sc. (Hons I) from the University of
New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was
a Fulbright Fellow and General Foods Scholar.
About Trovagene, Inc.
Trovagene is a clinical-stage, oncology therapeutics company,
taking a precision medicine approach to develop drugs that target
mitosis (cell division) to treat various types of cancer, including
leukemias, lymphomas and solid tumors. Trovagene has intellectual
property and proprietary technology that enables the Company to
analyze circulating tumor DNA (ctDNA) and clinically actionable
markers to identify patients most likely to respond to specific
cancer therapies. Trovagene plans to continue to vertically
integrate its tumor genomics technology with the development of
targeted cancer therapeutics. For more information, please
visit
https://www.trovageneoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
our need for additional financing; our ability to continue as a
going concern; clinical trials involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies
and trials may not be predictive of future trial results; our
clinical trials may be suspended or discontinued due to unexpected
side effects or other safety risks that could preclude approval of
our product candidates; uncertainties of government or third party
payer reimbursement; dependence on key personnel; limited
experience in marketing and sales; substantial competition;
uncertainties of patent protection and litigation;
dependence upon third parties; our ability to develop tests, kits
and systems and the success of those products; regulatory,
financial and business risks related to our international expansion
and risks related to failure to obtain FDA clearances or approvals
and noncompliance with FDA regulations. There are no guarantees
that any of our technology or products will be utilized or prove to
be commercially successful. Additionally, there are no
guarantees that future clinical trials will be completed or
successful or that any precision medicine therapeutics will receive
regulatory approval for any indication or prove to be commercially
successful. Investors should read the risk factors set forth
in Trovagene's Form 10-K for the year ended December 31, 2019,
and other periodic reports filed with the Securities and Exchange
Commission. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Forward-looking
statements included herein are made as of the date hereof, and
Trovagene does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Trovagene Contact:
Vicki
Kelemen
VP, Clinical Development and Investor Relations
858-952-7652
vkelemen@trovagene.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trovagene-announces-three-new-nominees-for-election-to-board-of-directors-301017000.html
SOURCE Trovagene, Inc.